🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Watch Neeraj Agarwal, MD, FASCO (Neeraj Agarwal, MD, FASCO) & Martin W. Schoen, MD, MPH (Martin Schoen MD MPH) discuss the latest #ProstateCancer updates NAVREF - to participate, visit: bit.ly/mCRPCT x.com/i/broadcasts/1…

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis sciencedirect.com/science/articl… This living meta-analysis (LMA) evaluates the differential efficacy of PARP

#OncologyData | @LARVOL Onco Data Podcast with Martin Schoen MD MPH x.com/i/broadcasts/1…

Martin Schoen MD MPH Oncology News Central Abhenil Mittal Journal of Clinical Oncology Using patients from LMICs without subsequent access, solely to get the drug approved in HICs, is unethical. thelancet.com/journals/lanam…

Valuing Clinical Strategies Immediately After FDA Approval jamanetwork.com/journals/jaman…

🚨 We need your help! 🏛 This Tuesday, March 11, 2025, Congress will begin votes on a continuing resolution that includes a devastating 57% cut to the Department of Defense’s Congressionally Directed Medical Research Program. The Prostate Cancer Research Program has been

3 consults this wk. PSA 1 or well below with no significant change. On ADT+ARPI, w/recommendation for chemo based on #PSMA “changes”. Rapidly discarding #ProstateCancer therapies likely is harming pts ⁦UroToday.com⁩ ⁦Journal of Clinical Oncology⁩ ⁦ASCO⁩ ascopubs.org/doi/10.1200/JC…

Great example of confounding that affects retrospective studies. This one seems rather obvious, both low-birth weight and/or prematurity should have accounted for in some way.

I had to check the calendar: it’s St Patrick’s Day, not April Fools Day. Did nature really run an article decrying unpaid labor in academia?!🤪 “First take the plank out of your own eye, and then you will see clearly to remove the speck from your brother's eye.” Matthew 7:5

VA study examines use of combination therapies for #mHSPC and outcomes in patients. Martin Schoen MD MPH Saint Louis University & Bruce Montgomery, MD Fred Hutch Cancer Center join Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss treatment patterns and outcomes for veterans with metastatic hormone-sensitive

On Mar. 29, we honor all Vietnam Veterans who served and sacrificed. VAs ongoing research addresses the unique health challenges Vietnam-era Veterans face. From toxic exposure to PTSD #VAResearch continues to shape policy and improve care for these heroes. research.va.gov/currents/0325-…

I call on all journalists to shed more light on the amazing developments that VA Research has made over the past century. It’s one of America’s Crown Jewels and worthy of exempting from current Resuction In Force initiatives. NAVREF military.com/history/not-ju…

LET’S PLAY DEVIL’S ADVOCATE: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?Tannock et al. Journal of Clinical Oncology argue - Modest iDFS, no OS benefit ( yet ) , high toxicity & censoring bias. I broke it down—with counterarguments . Do Check 👇 ascopubs.org/doi/10.1200/JC…

Combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) increased between 2013 and 2022 among veterans and was associated with longer overall survival. ja.ma/3RUlezS Martin Schoen MD MPH

A PCF-funded study shows newer combination therapies for metastatic prostate cancer are helping patients live longer. Using VA data, Martin Schoen MD MPH & team report that novel hormonal therapy delays relapse vs. chemotherapy, with similar overall survival. bit.ly/3GKkCul

Still too much ADT alone… In this VA study of 6216 veterans with de novo mHSPC: 📅 2022... and still 37% got only ADT! 🔵Combo therapy = longer OS (40.3 vs 33.0 mo) 🔵Not only biology, also delivery does matter! JAMA Network Open OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

Pasritamig, an hK2 x CD3 bispecific, was remarkably tolerable with low rates of CRS and had encouraging activity in mCRPC in the phase 1 trial.

Impactful work coming from VA data - here, earlier start of docetaxel (<4 months) better than >4 mo. Did inadequate response drive some of the later dosing? Excited to be collab w/ Dr Schoen thru ProfoundVET to improve #prostatecancer care #ASCO25 ⁦Jasnoor Malhotra⁩

Super proud of SLU Internal Medicine Residency SLU Medicine resident Sumrah Khan and her poster on tumor suppressor gene mutations and Lu-PSMA-177, which are associated with inferior survival in Veterans Affairs supported by Prostate Cancer Foundation and CDMRP

Great job Ariana Naaseh, MD, MPHS with your poster on male and female breast cancer in the Veterans Affairs that included over 2000 men and 13000 women. Shows men are older when diagnosed and have more advanced disease with shorter survival. Great collaboration of SLU Medicine and General Surgery Residency at WashU Medicine